Article
Selective killing of cancer cells based on loss of heterozygosity and normal variation in the human genome: a new paradigm for anticancer drug therapy.
Molecular pharmacology - 1 Aug 1999
Basilion J P, Schievella A R, Burns E, Rioux P, Olson J C, Monia B P, Lemonidis K M, Stanton V P, Housman D E
Abstract excerpt
Most drugs for cancer therapy are targeted to relative differences in the biological characteristics of cancer cells and normal cells. The therapeutic index of such drugs is theoretically limited by the magnitude of such differences, and most anticancer drugs have considerable toxicity to normal cells. Here we describe a new approach for developing anticancer drugs. This approach, termed variagenic targeting,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.